Heart Drug Stock Rockets 20% On Sales, Boosts Outlook; Regeneron Pharma's Global Partnership Strong Tailwind

investors.com/research/biotech-stock-heart-drug-kiniksa-knsa/?src=A00220

Kiniksa Pharmaceuticals (KNSA) shares currently hover just below a buy point, making the biotech stock Tuesday's choice for IBD 50 Stocks To Watch. The Lexington, Mass.-based drugmaker focuses on treatments for rare diseases. Its primary drug Arcalyst treats recurring pericarditis, a…

This story appeared on investors.com, 2025-07-01 17:37:15.
The Entire Business World on a Single Page. Free to Use →